Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Treatment of sleep apnea in congestive heart failure with a dental device - The effect on brain natriuretic peptide and quality of life

Eskafi, Mahmoud ; Cline, Charles ; Nilner, Maria and Israelsson, Bo LU (2006) In Sleep and Breathing 10(2). p.90-97
Abstract
The aim of the present study was to investigate the effect of a mandibular advancement device (MAD) for the treatment of sleep apnea (SA) on plasma brain natriuretic peptide (BNP), left ventricular ejection fraction (LVEF), and health-related qualify of life (HRQL) in patients with mild to moderate stable congestive heart failure (CHF). Seventeen male patients aged 68.4 +/- 5.5 with an apnea-hypopnea index (AHI) = 10 were equipped with an individually fitted MAD. SA was evaluated using a portable respiratory multirecording system before and after the initiation of treatment. Eleven patients completed follow-up and were evaluated after 6 months of treatment. The AHI reduced from 25.4 +/- 10.3 to 16.5 +/- 10.0 (p = 0.033) compared to... (More)
The aim of the present study was to investigate the effect of a mandibular advancement device (MAD) for the treatment of sleep apnea (SA) on plasma brain natriuretic peptide (BNP), left ventricular ejection fraction (LVEF), and health-related qualify of life (HRQL) in patients with mild to moderate stable congestive heart failure (CHF). Seventeen male patients aged 68.4 +/- 5.5 with an apnea-hypopnea index (AHI) = 10 were equipped with an individually fitted MAD. SA was evaluated using a portable respiratory multirecording system before and after the initiation of treatment. Eleven patients completed follow-up and were evaluated after 6 months of treatment. The AHI reduced from 25.4 +/- 10.3 to 16.5 +/- 10.0 (p = 0.033) compared to baseline and mean plasma BNP levels decreased from 195.8 +/- 180.5 pg/ml to 148.1 +/- 139.9 pg/ml (p = 0.035). SA-related symptoms, e. g., excessive daytime sleepiness, were also reduced (p = 0.003). LVEF and HRQL were unchanged. We conclude that SA treatment with a MAD on patients with mild to moderate stable CHF appears to result in the reduction of plasma BNP levels. Further studies to investigate if the observed reduction in BNP concentrations also result in improved prognosis are warranted. (Less)
Please use this url to cite or link to this publication:
author
; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
brain natriuretic peptide, mandibular advancement device, congestive heart failure, sleep apnea, quality of life
in
Sleep and Breathing
volume
10
issue
2
pages
90 - 97
publisher
Springer
external identifiers
  • wos:000244341900007
  • scopus:33746871128
ISSN
1522-1709
DOI
10.1007/s11325-006-0053-2
language
English
LU publication?
yes
id
d923675c-426e-431f-bcf8-84eaf0a4d111 (old id 672917)
date added to LUP
2016-04-01 11:38:55
date last changed
2022-03-12 22:39:21
@article{d923675c-426e-431f-bcf8-84eaf0a4d111,
  abstract     = {{The aim of the present study was to investigate the effect of a mandibular advancement device (MAD) for the treatment of sleep apnea (SA) on plasma brain natriuretic peptide (BNP), left ventricular ejection fraction (LVEF), and health-related qualify of life (HRQL) in patients with mild to moderate stable congestive heart failure (CHF). Seventeen male patients aged 68.4 +/- 5.5 with an apnea-hypopnea index (AHI) = 10 were equipped with an individually fitted MAD. SA was evaluated using a portable respiratory multirecording system before and after the initiation of treatment. Eleven patients completed follow-up and were evaluated after 6 months of treatment. The AHI reduced from 25.4 +/- 10.3 to 16.5 +/- 10.0 (p = 0.033) compared to baseline and mean plasma BNP levels decreased from 195.8 +/- 180.5 pg/ml to 148.1 +/- 139.9 pg/ml (p = 0.035). SA-related symptoms, e. g., excessive daytime sleepiness, were also reduced (p = 0.003). LVEF and HRQL were unchanged. We conclude that SA treatment with a MAD on patients with mild to moderate stable CHF appears to result in the reduction of plasma BNP levels. Further studies to investigate if the observed reduction in BNP concentrations also result in improved prognosis are warranted.}},
  author       = {{Eskafi, Mahmoud and Cline, Charles and Nilner, Maria and Israelsson, Bo}},
  issn         = {{1522-1709}},
  keywords     = {{brain natriuretic peptide; mandibular advancement device; congestive heart failure; sleep apnea; quality of life}},
  language     = {{eng}},
  number       = {{2}},
  pages        = {{90--97}},
  publisher    = {{Springer}},
  series       = {{Sleep and Breathing}},
  title        = {{Treatment of sleep apnea in congestive heart failure with a dental device - The effect on brain natriuretic peptide and quality of life}},
  url          = {{http://dx.doi.org/10.1007/s11325-006-0053-2}},
  doi          = {{10.1007/s11325-006-0053-2}},
  volume       = {{10}},
  year         = {{2006}},
}